Matches in SemOpenAlex for { <https://semopenalex.org/work/W2110273161> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2110273161 endingPage "3416" @default.
- W2110273161 startingPage "3395" @default.
- W2110273161 abstract "Benign prostatic hyperplasia (BPH) is a common condition in aging men that is characterized bynonmalignant enlargement of the prostate gland, and is frequently accompanied by urinary obstruction, andlower urinary tract symptoms (LUST). Currently pharmacotherapy of BPH is based on two classes of drugs: α1-adrenoceptor (α1-AR) antagonists and α5-reductase inhibitors. It has been shown that α1-AR antagonistsreduce symptom scores and increase peak urinary flow rates in BPH. Of particular importance for BPH therapyare uroselective α1-AR antagonists for which the hypotensive related side-effect caused by α1-AR blockade isreduced. α5-Reductase inhibitors reduce prostate volume and symptom scores, while increasing peak urinaryflow rates. This review describes new α1-AR antagonists and 5α-reductase inhibitors in the treatment of BPH.The new α1-AR antagonists represent various structures such as quinazolines, phenylethylamines, piperidines,and arylpiperazines.5α-Redu ctase inhibitors are classified into two groups: steroidal and non-steroidal. Thenewer non-steroidal inhibitors include derivatives of benzo[c]quinolizinones, benzo[f]quinolonones,piperidones and carboxylic acids. Besides the development of new compounds belonging to the abovementioned groups, new agents for BPH treatment are sought among combined 5α-reductase/α1-AR inhibitors,endothelins, androgen receptors antagonists, growth factors, estrogens and phosphodiesterase isoenzymes aswell as several phytomedicines, used for prevention and treatment of prostate disorders. These new agents canbe used for the design of future targets and development of new drugs in the treatment of BPH. The discoveryof a number of active leads may also ultimately help in developing new safe and effective drugs. Keywords: Benign prostatic hyperplasia, a1α-adrenoceptor antagonists, 5α-reductase inhibitors" @default.
- W2110273161 created "2016-06-24" @default.
- W2110273161 creator A5052164929 @default.
- W2110273161 creator A5076818213 @default.
- W2110273161 date "2006-12-01" @default.
- W2110273161 modified "2023-09-24" @default.
- W2110273161 title "Trends in the Development of New Drugs for Treatment of Benign Prostatic Hyperplasia" @default.
- W2110273161 doi "https://doi.org/10.2174/092986706779010315" @default.
- W2110273161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17168713" @default.
- W2110273161 hasPublicationYear "2006" @default.
- W2110273161 type Work @default.
- W2110273161 sameAs 2110273161 @default.
- W2110273161 citedByCount "14" @default.
- W2110273161 countsByYear W21102731612013 @default.
- W2110273161 countsByYear W21102731612015 @default.
- W2110273161 countsByYear W21102731612016 @default.
- W2110273161 countsByYear W21102731612022 @default.
- W2110273161 countsByYear W21102731612023 @default.
- W2110273161 crossrefType "journal-article" @default.
- W2110273161 hasAuthorship W2110273161A5052164929 @default.
- W2110273161 hasAuthorship W2110273161A5076818213 @default.
- W2110273161 hasConcept C121608353 @default.
- W2110273161 hasConcept C126322002 @default.
- W2110273161 hasConcept C126894567 @default.
- W2110273161 hasConcept C134018914 @default.
- W2110273161 hasConcept C134651460 @default.
- W2110273161 hasConcept C181199279 @default.
- W2110273161 hasConcept C185592680 @default.
- W2110273161 hasConcept C2776235491 @default.
- W2110273161 hasConcept C2777562237 @default.
- W2110273161 hasConcept C2779478474 @default.
- W2110273161 hasConcept C55493867 @default.
- W2110273161 hasConcept C71924100 @default.
- W2110273161 hasConcept C77411442 @default.
- W2110273161 hasConcept C98274493 @default.
- W2110273161 hasConceptScore W2110273161C121608353 @default.
- W2110273161 hasConceptScore W2110273161C126322002 @default.
- W2110273161 hasConceptScore W2110273161C126894567 @default.
- W2110273161 hasConceptScore W2110273161C134018914 @default.
- W2110273161 hasConceptScore W2110273161C134651460 @default.
- W2110273161 hasConceptScore W2110273161C181199279 @default.
- W2110273161 hasConceptScore W2110273161C185592680 @default.
- W2110273161 hasConceptScore W2110273161C2776235491 @default.
- W2110273161 hasConceptScore W2110273161C2777562237 @default.
- W2110273161 hasConceptScore W2110273161C2779478474 @default.
- W2110273161 hasConceptScore W2110273161C55493867 @default.
- W2110273161 hasConceptScore W2110273161C71924100 @default.
- W2110273161 hasConceptScore W2110273161C77411442 @default.
- W2110273161 hasConceptScore W2110273161C98274493 @default.
- W2110273161 hasIssue "28" @default.
- W2110273161 hasLocation W21102731611 @default.
- W2110273161 hasLocation W21102731612 @default.
- W2110273161 hasOpenAccess W2110273161 @default.
- W2110273161 hasPrimaryLocation W21102731611 @default.
- W2110273161 hasRelatedWork W1559582992 @default.
- W2110273161 hasRelatedWork W1978630268 @default.
- W2110273161 hasRelatedWork W2013357874 @default.
- W2110273161 hasRelatedWork W2023520015 @default.
- W2110273161 hasRelatedWork W2315566441 @default.
- W2110273161 hasRelatedWork W2330542927 @default.
- W2110273161 hasRelatedWork W2414475439 @default.
- W2110273161 hasRelatedWork W2743741616 @default.
- W2110273161 hasRelatedWork W2895588108 @default.
- W2110273161 hasRelatedWork W3175503089 @default.
- W2110273161 hasVolume "13" @default.
- W2110273161 isParatext "false" @default.
- W2110273161 isRetracted "false" @default.
- W2110273161 magId "2110273161" @default.
- W2110273161 workType "article" @default.